DelveInsight’s “Idiopathic Pulmonary Fibrosis (IPF) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Idiopathic Pulmonary Fibrosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Idiopathic Pulmonary Fibrosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Idiopathic Pulmonary Fibrosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Idiopathic Pulmonary Fibrosis (IPF): An Overview
The term “idiopathic” refers to a condition that has no known cause. Scarring produces stiffness in the lungs, making breathing harder. The most prevalent type of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). It is a lung illness that produces scarring (fibrosis).
Scarring produces stiffness in the lungs, making breathing harder. IPF causes irreversible and progressive lung damage, which means it becomes worse over time. Certain drugs can help to slow it down in some circumstances. Lung transplantation is occasionally indicated for persons with IPF.
There are several diagnostic tools available and the consensus guidelines have been well-defined to identify IPF. Pulmonary function tests are performed to assess for restrictive lung disease which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity. When IPF is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging is like X-rays, but they are not detailed enough to confirm IPF. High-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.
Idiopathic Pulmonary Fibrosis (IPF) Market Key Facts
-
The Idiopathic Pulmonary Fibrosis market size in seven major markets was USD 3,167 million in 2021
-
The United States accounts for the largest Idiopathic Pulmonary Fibrosis market size, with approximately USD 2,321 million in 2021, and is expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 6.3% for the study period (2019–2032).
-
The total Idiopathic Pulmonary Fibrosis market size in the EU-5 was USD 693 million in 2021, which is anticipated to grow at a CAGR of 7.8%.
-
Japan accounted for USD 153 million market share in 2021 i.e. 5% of the total Idiopathic Pulmonary Fibrosis market size in the 7MM.
-
The total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM was 194,000+ cases in 2021 which is expected to rise, at a CAGR of 1.1% during the study period (2019–2032).
-
The highest diagnosed prevalent cases of IPF were registered in the US in 2021, with 94,736 cases.
-
Among the European countries, Germany had the highest diagnosed prevalent population of IPF with 20,774 cases, followed by the UK with 15,760 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
-
Idiopathic Pulmonary Fibrosis companies working in the market are FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
Idiopathic Pulmonary Fibrosis (IPF) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Idiopathic Pulmonary Fibrosis pipeline therapies. It also thoroughly assesses the Idiopathic Pulmonary Fibrosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Idiopathic Pulmonary Fibrosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Idiopathic Pulmonary Fibrosis (IPF) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Idiopathic Pulmonary Fibrosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Idiopathic Pulmonary Fibrosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Idiopathic Pulmonary Fibrosis (IPF) Epidemiology, Segmented as –
-
Diagnosed prevalent cases of idiopathic pulmonary fibrosis in the 7MM (2019-32)
-
Gender-specific diagnosed prevalent cases of idiopathic pulmonary fibrosis in the 7MM (2019-32)
-
Age-specific diagnosed prevalent cases of idiopathic pulmonary fibrosis in the 7MM (2019-32)
-
Severity-specific diagnosed prevalent cases of idiopathic pulmonary fibrosis in the 7MM (2019-32)
Idiopathic Pulmonary Fibrosis (IPF) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to be launched during the study period. The analysis covers the Idiopathic Pulmonary Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Idiopathic Pulmonary Fibrosis drugs based on their sale and market share.
The report also covers the Idiopathic Pulmonary Fibrosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Idiopathic Pulmonary Fibrosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Idiopathic Pulmonary Fibrosis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Analysis
The therapeutic approach of IPF involves both nonpharmacological and pharmacological strategies. The goal of the treatment is to slow disease progression, reduce symptoms, prevent acute exacerbations, and prolong survival. There are two antifibrotic agents ESBRIET (Roche) and OFEV (Boehringer Ingelheim) approved for use in IPF. Both drugs are known to slow the disease progression but do not significantly impact mortality.
Upcoming Idiopathic Pulmonary Fibrosis therapies such as Pamrevlumab, PRM-151 (pentraxin-2, RG6354), Tyvaso (treprostinil), BI 1015550, and others have the potential to create a significant positive shift in the Idiopathic Pulmonary Fibrosis market size.
To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Idiopathic Pulmonary Fibrosis. Currently, Hoffmann-La Roche is leading the therapeutics market with its Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage of clinical development.
Idiopathic Pulmonary Fibrosis (IPF) Companies Actively Working in the Therapeutics Market Include
Algernon Pharmaceuticals, Astra Zeneca, Avalyn Pharmaceuticals, Bellerophon Therapeutics, Boehringer Ingelheim, Bridge Biotherapeutics, Bristol-Myers Squibb, Calliditas Therapeutics, Celgene Pharmaceutical, CSL Behring, Daewoong Pharmaceutical, Endeavor BioMedicines, FibroGen, Galecto Biotech AB, Guangdong Raynovent, Horizon Therapeutics, Insmed, Kadmon Pharmaceuticals, Kinarus AG, Lung Therapeutics, MediciNova, Metagone Biotech, Nitto Denko, Novartis, Pliant Therapeutics, PureTech Health, Regend Therapeutics, Roche, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Syndax Pharmaceuticals, Taiho Pharmaceutical, United Therapeutics, Vicore Pharma, and others.
Emerging and Marketed Idiopathic Pulmonary Fibrosis (IPF) Therapies Covered in the Report Include:
-
BG-00011: Biogen
-
BMS-986020: Bristol-Myers Squibb
-
CC-90001: Celgene Corporation
-
ESBRIET (Pirfenidone): Hoffmann-La Roche Ltd
-
Gefapixant: Merck & Co., Inc.
-
GLPG4716: Galapagos NV
-
LT-1002: Chong Kun Dang Pharmaceutical
-
OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
-
Pamrevlumab: FibroGen, Inc.
-
PBI4050: ProMetic Life Sciences
-
PLN-74809: Pliant Therapeutics
-
PRM-151 (RG6354): Hoffmann-La Roche Ltd
-
TAS-115: Taiho Pharmaceutical
-
TD139 (Bristol-Myers Squibb
-
Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
-
Tipelukast: MediciNova
-
Tyvaso (inhaled treprostinil): United Therapeutics
-
VAY-736: MorphoSys; Novartis
And Many Others
The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis
4. Idiopathic Pulmonary Fibrosis Market Overview at a Glance
5. Idiopathic Pulmonary Fibrosis Disease Background and Overview
6. Idiopathic Pulmonary Fibrosis Patient Journey
7. Idiopathic Pulmonary Fibrosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Idiopathic Pulmonary Fibrosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Idiopathic Pulmonary Fibrosis Unmet Needs
10. Key Endpoints of Idiopathic Pulmonary Fibrosis Treatment
11. Idiopathic Pulmonary Fibrosis Marketed Therapies
12. Idiopathic Pulmonary Fibrosis Emerging Drugs and Latest Therapeutic Advances
13. Idiopathic Pulmonary Fibrosis Seven Major Market Analysis
14. Attribute Analysis
15. Idiopathic Pulmonary Fibrosis Market Outlook (In US, EU5, and Japan)
16. Idiopathic Pulmonary Fibrosis Companies Active in the Market
17. Idiopathic Pulmonary Fibrosis Access and Reimbursement Overview
18. KOL Views on the Idiopathic Pulmonary Fibrosis Market
19. Idiopathic Pulmonary Fibrosis Market Drivers
20. Idiopathic Pulmonary Fibrosis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Lipodystrophy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Lipodystrophy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Lipodystrophy market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices